SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has signed memorandums of understanding with Samyang Holdings to advance development of a messenger ribonucleic acid (mRNA) vaccine for COVID-19 and with GC Pharma to develop mRNA vaccines and therapeutics for respiratory infections and other diseases more broadly.

By A Silva